



Solid Research
Solid Relationships

Fundamental Outlook

Global Market Setup

- **US stocks closed higher on Tuesday**, with tech stocks leading the charge as renewed enthusiasm for artificial intelligence offset concerns over potential disruptions caused by the nascent technology..
- **Dow** closed **higher by +0.8%**, **S&P 500** was **up by +0.8%** and **Nasdaq** ended **+1.1%**.
- **Major European** Indices ended on a **mixed note**
- **Dow futures** are currently trading **+0.1% higher**
- Most of the **Asian markets** are trading 1-2% higher, after a rally in technology shares lifted Wall Street benchmarks, tempering concern about the disruptive effects of artificial intelligence that had rattled markets for weeks.

Global Cues: Positive

Indian Market Setup

- Markets remained volatile on Tuesday amid continued global uncertainty and fresh concerns around AI-driven disruption. The weekly derivatives expiry further heightened intraday fluctuations.
- **Nifty50 was down by 1% to close at 25,459 (-254pts).**
- **Midcap index down by 0.3% and the Smallcap index down by 0.6%.**
- **FIIIs: -102cr; DIIs: +3,161cr**
- **Gift nifty is currently trading 80 points higher (+0.3%)**

Domestic Cues: Slightly positive

Stocks in News

Dr Reddy's: The company has received a letter from the US SEC stating that, based on the available information, the SEC has concluded its investigation and does not intend to recommend any enforcement action against the company at this time. The company had initiated a detailed investigation into an anonymous complaint alleging improper payments to healthcare professionals in Ukraine and potentially other countries, which could constitute a violation of US anti-corruption laws, including the US Foreign Corrupt Practices Act. The matter was accordingly disclosed to the US Department of Justice, the US SEC, and SEBI. The company also engaged a US law firm to conduct the investigation.

View: Positive

Power Grid: The Cabinet Committee on Economic Affairs has increased the permissible equity investment limit of Power Grid from the current threshold of Rs 5,000 crore per subsidiary to Rs 7,500 crore per subsidiary, while retaining the existing cap of 15 percent of the company's net worth.

View: Positive

Fundamental Actionable Idea

Polycab India

CMP INR8121, TP INR9600, 18% Upside, Buy, MTF Stock

- Channel inventory, which had risen to ~40-45 days in 3QFY26 (vs. normal ~21-24 days), normalized within the first 20 days of Jan'26 amid strong demand recovery. The company has now passed on the entire cost increase (vs. ~70% in 3Q), driving margin recovery in 4QFY26.
- It has gained meaningful market share in 9MFY26, growing well ahead of industry, and it has reiterated its 1.5x industry growth target till FY30 under Project Spring. Real estate demand remains strong, while affordable housing and government's City Economic Region push should further support wire demand.
- Unorganized players account for ~40% of wires, & POLYCAB sees limited impact from new entrants. It holds ~30% share in organized wires, aided by a strong network of dealers and distributors (200k+ electricians/retailers), structured loyalty programs, and 34 warehouses enabling 24-hour replenishment.
- Exports form ~6% of revenue (target 10%+ by FY30). With reduced tariff, US/Europe offer incremental opportunities amid China+1 sourcing shift. The company is strengthening its US distribution footprint.
- We remain structurally positive on POLYCAB, supported by its leadership in the C&W segment, a favorable industry outlook, a strong balance sheet, and healthy return ratios, providing visibility for steady growth and capital efficiency.

View: BUY

Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Fundamental Actionable Idea

Lupin

CMP INR 2252, MTF Stock

- The pharma company has received approval from the US FDA for its ANDA for Brivaracetam Oral Solution 10 mg/mL. Brivaracetam is used for the treatment of partial-onset seizures in patients aged one month and older.
- Brivaracetam Oral Solution (RLD: Briviact) had estimated annual sales of \$135 million in the US.
- Also received European Commission approval for its Ranibizumab biosimilar, strengthening its biosimilars portfolio in Europe.
- Management expects the USD1bn US run-rate to sustain into FY27, supported by traction in Tolvaptan, Mirabegron and g-Spiriva, while R&D intensity will rise as the company builds a complex and biosimilar pipeline.
- Emerging markets are recovering well, and domestic formulations continue to grow ahead of IPM excluding in-licensed products.
- **View: Positive**

Target Achieved



24% Gains

Reco Date	Call Type	Reco Price
23 th Jan'26	Investment Idea	₹142

Today Price	Date	Return	Duration
₹177	24 th Feb'26	24% Gain	1 month

This is strictly for internal circulation only and such material should not be redistributed.
Investments in securities market are subject to market risks, read all the related documents carefully before investing.

Investment in securities market are subject to market risks, read all the related documents carefully before investing.

- The life insurance industry has delivered strong growth and margin performance, supported by GST waiver, new product launches, recovery in ULIP momentum, improving mix toward protection and non-par, and strong rider growth.
- Following the GST exemption from 22nd Sep'25, individual APE witnessed double-digit growth in subsequent months, supporting margin expansion and reinforcing growth visibility for the sector, despite the loss of input tax credit.
- In general insurance, retail health momentum & recovery in motor are driving steady premium growth. Despite competitive intensity, private players remain focused on profitable growth, supporting stable return profiles.

Time Frame: 12 months

Review: Monthly

Upside: 15 -20%

Risk: High

Benchmark: Nifty 200

Script	CMP as on 24 th Feb 2025	Weightage (%)
Max Life	1842	20
SBI Life	2083	20
ICICI Prudential Life	661	20
Canara HSBC	150	20
ICICI Lombard	1904	20

Weightage Rationale: We have assigned equal weightage to all the stocks in the basket as we expect equal growth opportunity in each of them.

*Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Focus Investment Ideas

All Stocks Available in MTF

Duration : 1 Year Horizon

Stock Name	Rating	CMP (₹)	Target (₹)	Upside (%)
Delhivery	Buy	437	580	33%
JK Cement	Buy	5626	6780	21%
TVS Motor	Buy	3816	4461	17%
Syrma SGS	Buy	827	1000	21%
Max Financial	Buy	1842	2200	19%

Technical Outlook

Nifty Technical Outlook

NIFTY (CMP : 25426) Nifty immediate support is at 25300 then 25200 zones while resistance at 25550 then 25650 zones. Now till it holds below 25500 zones, weakness could be seen towards 25300 then 25200 zones while hurdles are placed at 25550 then 25650 zones.

5-Nifty50 - 24/02/26
EMA(CloseLine:200)



Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Bank Nifty Technical Outlook

BANK NIFTY (CMP : 61047) Bank Nifty support is at 60750 then 60500 zones while resistance at 61250 then 61500 zones. Now it has to hold above 61000 zones for an up move towards 61250 then 61500 levels while a hold below the same some weakness could be seen towards 60750 then 60500 zones.

5-Niftybank - 24/02/26
EMA(CloseLine:20)



Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Sensex Technical Outlook

Sensex (CMP : 82225) Sensex support is at 82000 then 81700 zones while resistance at 82500 then 82800 zones. Now till it holds below 82500 zones weakness could be seen towards 82000 then 81700 zones while hurdles have shifted lower to 82500 then 82800 zones.


5-S&P BSESENSX - 24/02/26
EMA(CloseLine:200)



Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Midcap100 Index Technical Outlook

25-Feb-26



Nifty Midcap100 Stats

Advance	Decline
50	50

- Formed a Dragonfly Doji candlestick at its 200 DEMA support.

Smallcap250 Index Technical Outlook

25-Feb-26



Nifty SmallCap250 Stats

Advance	Decline
80	170

- Consolidating within a range below its 50 DEMA.

Investment in securities market are subject to market risks, read all the related documents carefully before investing.


Sectoral Performance - Daily

25-Feb-26

Indices	Closing	% Change			
	24-Feb	1-day	2-days	3-days	5-days
NIFTY 50	25425	-1.12%	-0.57%	-0.12%	-1.17%
NIFTY BANK	61047	-0.35%	-0.20%	0.51%	-0.21%
NIFTY MIDCAP 100	59066	-0.32%	-0.75%	-0.27%	-1.35%
NIFTY SMALLCAP 250	15933	-0.59%	-0.16%	-0.34%	-1.03%
NIFTY FINANCIAL SERVICES	28295	-0.56%	0.30%	0.80%	0.03%
NIFTY PRIVATE BANK	28873	-0.47%	-0.12%	0.39%	-0.55%
 NIFTY PSU BANK	9825	0.29%	1.65%	3.36%	3.41%
 NIFTY IT	30054	-4.74%	-6.09%	-7.01%	-9.14%
NIFTY FMCG	52235	0.19%	0.89%	1.46%	0.88%
 NIFTY OIL & GAS	12211	0.50%	0.99%	1.46%	1.16%
NIFTY PHARMA	22632	0.24%	0.80%	0.90%	0.61%
NIFTY AUTO	27950	-0.45%	0.37%	0.78%	-0.80%
 NIFTY METAL	12074	0.93%	0.70%	1.95%	2.08%
NIFTY REALTY	798	-2.54%	-2.72%	-2.33%	-4.29%
NIFTY INDIA DEFENCE	8020	-0.60%	-0.99%	-0.21%	-1.25%

- Among sectoral indices Nifty PSU Bank, Metal & Oil & Gas were the top gainers while weakness continues in Nifty IT.

Sectoral Performance - Weekly

Name	1W Change	2W Change	3W Change	4W Change	5W Change
Nifty 50	-0.57	-0.18	-1.05	0.41	1.5
Nifty Bank	-0.2	1.43	1.54	2.41	4.4
 Nifty IT	-6.09	-8.04	-15.61	-20.99	-21.41
Nifty Auto	0.37	-1.01	1.56	4.48	4.27
Nifty Metal	0.7	1.69	1.09	2.08	5.19
Nifty Pharma	0.8	1.97	3.05	4.22	4.19
Nifty FMCG	0.89	2.62	0.68	1.99	1.11
Nifty Realty	-2.72	-3.07	-3.21	1.96	5.55
Nifty Media	-1.11	-3.55	1.45	1.86	4.39
 Nifty PSU Bank	1.65	7.18	10.69	8.93	11.89

- Among the Sectoral Indices weakness continues in Nifty IT while Strength was seen in Nifty PSU Bank.

Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Technical – Conviction Delivery Idea

NTPC

(Mcap ₹ 3,71,140 Cr.)

F&O Stock, MTF stock

- Trendline breakout on daily chart.
- Strong bodied bearish candle.
- Respecting 20 DEMA.
- Surge in traded volumes.
- RSI momentum indicator showing strength.
- We recommend to buy the stock at CMP ₹383 with a SL of ₹370 and a TGT of ₹406.

RECOs	CMP	SL	TARGET	DURATION
BUY	383	370	406	1 Week



Technical Stocks On Radar

JINDALSTEL

(CMP: 1233, Mcap ₹ 1,25,807 Cr.)

F&O Stock, MTF stock


- Overall uptrend.
- Respecting 20 DEMA support.
- High traded volumes.
- RSI indicator confirming positive momentum.
- Immediate support at 1150.

ASTRAL

(CMP: 1664, Mcap ₹ 44,703 Cr.)

F&O Stock, MTF stock

- Bullish “Pole & Flag” pattern
- Strong bullish candle.
- RSI momentum indicator rising.
- Immediate support at 1580.



25-Feb-26

Technical Chart Pattern for the Day

IOC (Mcap ₹ 2,54,451 Cr.) (CMP : 180) F&O Stock, MTF stock

25-Feb-26



- Bullish “Pennant” chart pattern pattern; Support : 170

Derivative Outlook

Nifty : Option Data

- Maximum Call OI is at 25500 then 26000 strike while Maximum Put OI is at 25500 then 25000 strike.
- Call writing is seen at 25500 then 25600 strike while Put writing is seen at 25000 then 25500 strike.
- Option data suggests a broader trading range in between 25000 to 25800 zones while an immediate range between 25200 to 25600 levels.



Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Option - Buying side strategy

Index	Single Leg Buying	Multi Leg Strategy
Nifty (Weekly)	25300 PE if it holds below 25500	Bear put spread (Buy 25300 PE and Sell 25200 PE) at net premium cost of 20-25 points
Sensex (Monthly)	81900 PE till it holds below 82500	Bear put spread (Buy 81900 PE and Sell 81700 PE) at net premium cost of 40-50 points
Bank Nifty (Monthly)	63000 CE till it holds above 61000	Bull call spread (Buy 61500 CE and Sell 62000 CE) at net premium cost of 220-240 points

Option - Selling side strategy

Index	Writing
Nifty (Weekly)	24400 PE and 26200 CE
Sensex (Monthly)	80600 PE and 83900 CE
Bank Nifty (Monthly)	57500 PE and 64000 CE

Weekly Option Range for Option Writers based on Different Confidence Band								
Date	25-Feb-26	Weekly Expiry	2-Mar-26	Days to weekly expiry	4			
Nifty		25425	India VIX		14.2			
Confidence Band	Probability	% Away From Spot	Range				Total Premium (Put + Call)	Types of Trades
			Put	Premium	Call	Premium		
1.00	68%	± 1.5%	25050	54	25750	69	122	Aggressive
1.25	79%	± 1.9%	24950	41	25850	46	87	Less Aggressive
1.50	87%	± 2.3%	24850	31	25950	31	62	Neutral
1.75	92%	± 2.7%	24750	25	26050	20	45	Conservative
2.00	95%	± 3.0%	24650	20	26150	14	33	Most Conservative
Date	25-Feb-26	Monthly Expiry	30-Mar-26	Days to weekly expiry	24			
Bank Nifty		61047						
Confidence Band	Probability	% Away From Spot	Range				Total Premium (Put + Call)	Types of Trades
			Put	Premium	Call	Premium		
1.00	68%	± 3.0%	59200	258	62800	309	567	Aggressive
1.25	79%	± 3.7%	58800	209	63200	226	435	Less Aggressive
1.50	87%	± 4.5%	58300	160	63700	142	302	Neutral
1.75	92%	± 5.2%	57900	126	64100	101	227	Conservative
2.00	95%	± 6.0%	57400	103	64600	63	166	Most Conservative


Investments in securities markets are subject to market risks. Please read all related documents carefully.

Nifty Advance Decline & Ban update

Stocks in Ban:

Nil

All FNO **Nifty 50** Bank Nifty Fin Nifty



Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Stocks : Options on radar

Stock	Call Strike	Trade	Buying Range	SL	TGT	Logic
TORNTPHARM	4400 CE	Buy	113-114	115	130	Short covering
AUBANK	1010 CE	Buy	31-32	29	36	Short covering
CGPOWER	730 CE	Buy	26-27	23	33	Short covering

Stock	Put Strike	Trade	Buying Range	SL	TGT	Logic
CDSL	1320 PE	Buy	40-41	35	50	Long liquidation
PERSISTENT	4600 PE	Buy	233-234	210	275	Long liquidation

Quant Outlook

Quant Intraday Sell Ideas

What is this?

Based on technical indicators this strategy gives 2 stocks that have a high likelihood to fall during the day (from open to close). This is an intraday Sell strategy which can provide a good cushioning during a black swan event.

Today's **Sell** Ideas:

Stock Names	Close Price	SL (1%)	TP (1%)
MAZDOCK (Sell)	2256	2278	2233
IRFC (Sell)	109	110	108

What are the rules?

- Stock names will be given at market open (9:15 am)
- Recommended time to entry: between 9:15 to 9:30 am.
- Entry: We short 2 stocks daily (intraday)
- Exit: we will exit at 3:15 as this is an intraday call
- SL: is placed at 1% of the open.
- Book profit: At 1% fall since open.
- In special situations the book profit might be delayed if the stock is in free fall.

Siddhartha Khemka
Head – Retail Research

Chandan Taparua, CMT, CFTe
Head – Derivatives & Technical Research

Ruchit Jain
Head – Technical Research

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

MOFSL, its associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report..

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- managed or co-managed public offering of securities from subject company of this research report,
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a marketmaker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement

Analyst ownership of the stock No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Disclaimer:

This report is intended for distribution to Retail Investors.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions-including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN.: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dp grievances@motilaloswal.com.

Investment in securities market are subject to market risks, read all the related documents carefully before investing.